Implications of intrinsic disorder and functional proteomics in the merkel cell polyomavirus life cycle

Nathan Lanclos1,2,3, Peter Radulovic1,4, Jackson Bland1

  • 1Department of Molecular Biosciences, College of Arts and Sciences, University of South Florida, Tampa, Florida, USA.

PubMed

Insights

Merkel cell polyomavirus (MCPyV) proteins exhibit intrinsic disorder, potentially driving merkel cell carcinoma (MCC) oncogenesis. This disorder may facilitate viral immune system evasion and inform new therapeutic strategies for this aggressive skin cancer.

Area of Science:

  • Virology
  • Computational Biology
  • Oncology

Background:

  • Merkel cell polyomavirus (MCPyV) is linked to merkel cell carcinoma (MCC), an aggressive skin cancer with increasing incidence and high mortality.
  • Understanding MCPyV pathogenesis is crucial for developing effective MCC treatments.
  • The role of intrinsic disorder in MCPyV proteins has not been previously investigated.

Purpose of the Study:

  • To computationally characterize intrinsic disorder within the MCPyV proteome.
  • To explore potential mechanisms by which intrinsic disorder contributes to viral oncogenicity.
  • To identify potential therapeutic targets for MCC.

Main Methods:

  • Computational analysis of MCPyV proteins (LT, ALTO, 57kT, sT, VP1) for intrinsic disorder.
  • Functional prediction of eukaryotic linear motifs (ELMs) and molecular recognition features (MoRFs).
  • Assessment of propensity for liquid-liquid phase separation (LLPS).

Main Results:

  • Significant intrinsic disorder was identified in MCPyV proteins LT, ALTO, 57kT, and VP1, with potential disorder in sT.
  • Disorder propensity correlated with ELMs, MoRFs, and LLPS.
  • Findings suggest MCPyV utilizes disorder and phase separation for oncogenic activities.

Conclusions:

  • Intrinsic disorder in MCPyV proteins is a key factor in viral oncogenesis.
  • MCPyV may exploit disorder and phase condensation to enhance viral function and immune evasion.
  • This study provides a foundation for experimental validation and the development of novel MCC therapeutics.